For instance, monitoring patients with metastatic breast cancer under treatment with Denosumab (anti-RANKL fully human IgG2 monoclonal antibody) demonstrated that the expression of RNAKL on circulating tumor cells (CTCs) is a pivotal step in the metastatic process affects the effectiveness of Denosumab (136). The gene discussed is TNFSF11; the disease is neoplasm.